George L. Sing - 02 Jan 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Jan 2026, 16:16:18 UTC
Prior SEC filing
31 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ George L. Sing

Key filing fact

George L. Sing filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 06 Jan 2026.

Key facts

  • This page summarizes George L. Sing's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 06 Jan 2026, 16:16.

Change

  • Previous filing in this sequence was filed on 31 Dec 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001225471 Primary reporting owner

SING GEORGE L

Relationship
Director
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature
/s/ George L. Sing
Signature date
06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Award

Transaction value
$0
Shares
+155
Change %
+0.5%
Price
$0.000000
Shares after
31,007
Date
02 Jan 2026
Ownership
Direct
Footnotes
F1
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
750
Date
02 Jan 2026
Ownership
by Spouse
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
400
Date
02 Jan 2026
Ownership
by Spouse/Cust Son
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,000
Date
02 Jan 2026
Ownership
by Trust for Son

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,962
Change %
Price
$0.000000
Shares after
1,962
Date
02 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,962
Exercise price
$772.76
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Footnote F2

On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .